IPO registrations (S-1, F-1) · Registrants
Savara Inc
- SEC CIK
- 1160308 · filings on EDGAR ↗
- Name on the registration
- Mast Therapeutics, Inc.
- Former names
- Mast Therapeutics, Inc. (2013–2017); ADVENTRX PHARMACEUTICALS INC (2003–2013); BIOKEYS PHARMACEUTICALS INC (2001–2003)
- Registration
- Form S-1, first filed 2009-07-24, last 2013-06-14; 2 initial registrations, 6 amendments
- Outcome
- Final prospectus filed 2009-10-06; declared effective 2009-10-06
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 6836 BEE CAVE ROAD, BUILDING 3, SUITE 201, Austin, TX 78746
- EIN
- 84-1318182
- Ticker
- SVRA (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Savara Inc on the corporate pages
Offering terms
- Final price
- $0.15 per share (424B4 filed 2009-10-06)
- Shares sold
- 11,283
- Gross proceeds
- $1,656 before underwriting discounts and any over-allotment option
- Listing
- NYSE American under the symbol ANX
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: MAST THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Form D issuer: Savara Inc EXACT (CIK (EXACT))
- SEC filer: ADVENTRX PHARMACEUTICALS INC EXACT (CIK (EXACT))
Filings 19
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2009-07-24 | S-1 | S-1 (registration) | ADVENTRX PHARMACEUTICALS INC | 0000950123-09-025323 ↗ |
| 2009-09-03 | S-1/A | S-1/A (amendment) | ADVENTRX PHARMACEUTICALS INC | 0000950123-09-040958 ↗ |
| 2009-09-25 | S-1/A | S-1/A (amendment) | ADVENTRX PHARMACEUTICALS INC | 0000950123-09-046120 ↗ |
| 2009-10-05 | S-1/A | S-1/A (amendment) | ADVENTRX PHARMACEUTICALS INC | 0000950123-09-048382 ↗ |
| 2009-10-06 | 424B4 | 424B4 (final prospectus) | ADVENTRX PHARMACEUTICALS INC | 0000950123-09-048646 ↗ |
| 2009-10-06 | S-1MEF | S-1MEF (added securities) | ADVENTRX PHARMACEUTICALS INC | 0000950123-09-048704 ↗ |
| 2009-10-06 | EFFECT | EFFECT (declared effective) | ADVENTRX PHARMACEUTICALS INC | 9999999995-09-002773 ↗ |
| 2010-03-23 | EFFECT | EFFECT (declared effective) | ADVENTRX PHARMACEUTICALS INC | 9999999995-10-000805 ↗ |
| 2010-04-01 | EFFECT | EFFECT (declared effective) | ADVENTRX PHARMACEUTICALS INC | 9999999995-10-000931 ↗ |
| 2011-05-11 | EFFECT | EFFECT (declared effective) | ADVENTRX PHARMACEUTICALS INC | 9999999995-11-001472 ↗ |
| 2011-10-13 | EFFECT | EFFECT (declared effective) | ADVENTRX PHARMACEUTICALS INC | 9999999995-11-002942 ↗ |
| 2012-05-01 | EFFECT | EFFECT (declared effective) | ADVENTRX PHARMACEUTICALS INC | 9999999995-12-001352 ↗ |
| 2013-05-28 | S-1 | S-1 (registration) | Mast Therapeutics, Inc. | 0001193125-13-236099 ↗ |
| 2013-06-05 | S-1/A | S-1/A (amendment) | Mast Therapeutics, Inc. | 0001193125-13-248742 ↗ |
| 2013-06-13 | S-1/A | S-1/A (amendment) | Mast Therapeutics, Inc. | 0001193125-13-257099 ↗ |
| 2013-06-14 | S-1/A | S-1/A (amendment) | Mast Therapeutics, Inc. | 0001193125-13-258655 ↗ |
| 2013-06-14 | EFFECT | EFFECT (declared effective) | Mast Therapeutics, Inc. | 9999999995-13-001808 ↗ |
| 2013-06-17 | 424B4 | 424B4 (final prospectus) | Mast Therapeutics, Inc. | 0001193125-13-261424 ↗ |
| 2014-05-14 | EFFECT | EFFECT (declared effective) | Mast Therapeutics, Inc. | 9999999995-14-001456 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2009-10-05 | S-1/A | registration statement | $0.15 | - | - | 0 | primary document; price line | document ↗ | ||
| 2009-10-06 | 424B4 | final prospectus | $0.15 | 11,283 | $1,656 | NYSE American ANX | 0 | primary document; price line, shares headline, proceeds computed | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Carlander Carrie | Officer | CFO, Treas, Secy, VP Finance | 1 | 2006 | |
| Culley Brian M | Director,Officer; Officer | CEO and Director; Chief Executive Officer; SVP & Chief Business Officer; VP, Business Development | 21 | 2006–2017 | |
| ROBBINS JOAN M | Officer | CSO, Exec VP; CSO, Exec. VP; CSO, Sr. VP; Senior VP and CS0; SVP & Chief Science Officer | 6 | 2006–2008 | |
| Cantwell Mark Joseph | Officer | VP, Research & Development | 2 | 2006–2007 | |
| LEVINE EVAN | Director,Officer | CEO & Director; CEO & President; President & CEO | 8 | 2006–2008 | |
| Bagnall Mark | Director; Director,Officer | CFO & Executive Vice President | 3 | 2006–2008 | |
| GOLDBERG MICHAEL M | Director | 6 | 2006–2010 | ||
| JOHNSON M ROSS | Director | 2 | 2006 | ||
| Meister Keith | Director | 2 | 2006 | ||
| PYKETT MARK JEROME | Director | 7 | 2006–2010 | ||
| Keran Patrick L | Officer | General Counsel; President and COO; President & COO; President, COO and Secretary; VP, Legal and General Counsel; VP, Legal & General Counsel | 15 | 2006–2015 | |
| Schupp Joachim PH | Officer | VP, Medical Affairs | 4 | 2006–2008 | |
| Daniel Robert A | Officer | Acting Chief Financial Officer | 2 | 2006 | |
| MERRITT JAMES A | Officer | President & Chf Med Officer | 4 | 2006–2007 | |
| LIEF JACK | Director | 11 | 2006–2015 | ||
| Denner Alexander J | Director | 5 | 2006–2009 | ||
| HANSON GREGORY P | Officer | Senior VP, CFO & Treasurer | 2 | 2006 | |
| Rowinsky Eric K | Director | 5 | 2008–2010 | ||
| Yelmene Michele | Officer | VP, Regulatory & QA; VP, Regulatory & Quality | 2 | 2008–2009 | |
| Erwin Mark E. | Officer | Senior VP, Operations; SVP, Operations | 2 | 2008–2009 | |
| Kostas Odysseas D | Director | 3 | 2010 | ||
| Roberts Brandi | Officer | Chief Financial Officer & SVP; Vice President, Finance | 12 | 2011–2017 | |
| Shuster Lewis | Director | 6 | 2011–2015 | ||
| EMANUELE ROBERT MARTIN | Officer | Senior VP, Development | 9 | 2011–2016 | |
| RAMSAY DAVID A | Director | 49 | 2011–2025 | ||
| Gorgas Gregory D. | Officer | Senior VP, Commercial | 10 | 2011–2016 | |
| Vetticaden Santosh | Officer | Chief Medical Officer & SVP | 5 | 2012–2014 | |
| LOVE TED W | Director | 3 | 2012–2013 | ||
| DITTRICH HOWARD | Director | 5 | 2014–2017 | ||
| Parsley Edwin L. | Officer | Chief Medical Officer & SVP; Interim Chief Medical Officer | 6 | 2014–2017 | |
| Pauls Matthew | Director; Director,Officer | CHIEF EXECUTIVE OFFICER; See Remarks | 25 | 2015–2025 | |
| Greenleaf Peter | Director | 4 | 2015–2017 | ||
| Hood Shana | Officer | General Counsel & VP | 2 | 2016–2017 | |
| Elam Nevan C | Director | 16 | 2017–2025 | ||
| Hawkins Richard J | Director | 15 | 2017–2025 | ||
| Jouhikainen Jaakko Taneli | Officer | President and COO; See Remarks | 7 | 2017–2019 | |
| Lowrance David L | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 20 | 2017–2026 | |
| McCracken Joseph S | Director | 16 | 2017–2026 | ||
| Neville Robert N | Director,Officer | Chief Executive Officer | 7 | 2017–2019 | |
| PIKOVER YURI | Director | 6 | 2017–2018 | ||
| Serenova a/s | TenPercentOwner | 1 | 2017 | ||
| Zambon Co SpA | TenPercentOwner | 1 | 2017 | ||
| Zambon SpA | TenPercentOwner | 1 | 2017 | ||
| Chowdhury Badrul A. | Officer | Chief Medical Officer; CHIEF MEDICAL OFFICER | 6 | 2019–2021 | |
| van Es-Johansson An | Director | 8 | 2019–2025 | ||
| Sun Ricky | Director | 6 | 2019–2023 | ||
| BASKETT FOREST | TenPercentOwner | 2 | 2021–2023 | ||
| Behbahani Ali | TenPercentOwner | 2 | 2021–2023 | ||
| Chang Carmen | TenPercentOwner | 2 | 2021–2023 | ||
| Florence Anthony A. Jr. | TenPercentOwner | 2 | 2021–2023 | ||
| Growth Equity Opportunities 17, LLC | TenPercentOwner | 2 | 2021–2023 | ||
| Landsman Liza | TenPercentOwner | 1 | 2021 | ||
| Makhzoumi Mohamad | TenPercentOwner | 2 | 2021–2023 | ||
| MAKOWER JOSHUA | TenPercentOwner | 1 | 2021 | ||
| Mathers Edward T | TenPercentOwner | 2 | 2021–2023 | ||
| NEA 17 GP, LLC | TenPercentOwner | 2 | 2021–2023 | ||
| NEA Partners 17, L.P. | TenPercentOwner | 2 | 2021–2023 | ||
| New Enterprise Associates 17, L.P. | TenPercentOwner | 2 | 2021–2023 | ||
| SANDELL SCOTT D | TenPercentOwner | 2 | 2021–2023 | ||
| Sonsini Peter W. | TenPercentOwner | 1 | 2021 | ||
| Walker Paul Edward | TenPercentOwner | 2 | 2021–2023 | ||
| Yang Rick | TenPercentOwner | 2 | 2021–2023 | ||
| Pratt Raymond Dennis | Officer | Chief Medical Officer | 7 | 2022–2024 | |
| Lutz Robert Matthew | Officer | Chief Fin. & Operating Officer; Chief Operating Officer | 7 | 2023–2026 | |
| Erickson Anne | Officer | Chief Business Officer | 6 | 2024–2025 | |
| Parker Braden C. | Officer | Chief Commercial Officer | 4 | 2024–2026 | |
| McCabe Kathleen R. | Officer | Chief Legal Officer | 2 | 2025 | |
| Wasfi Yasmine | Officer | Chief Medical Officer | 3 | 2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-01-02 | Savara Inc | Pharmaceuticals | $74,999,962 | $26,779,912 | 18 | 1 |
| 2014-03-05 | Mast Therapeutics, Inc. | Pharmaceuticals | $4,162,089 | $4,162,089 | 2 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form 5500 plan sponsor | MAST THERAPEUTICS, INC. | EIN (EXACT) | ||
| Form D issuer | Savara Inc | Form D private offerings | CIK (EXACT) | |
| SEC filer | ADVENTRX PHARMACEUTICALS INC | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.